TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27799178
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg perineurally with ropivacaine 0.5%
Study: 8640993
Drug: Sequential grafts
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential grafts
Study: 2890501
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus glyburide (IG)
Study: 11274902
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus placebo (IP)
Study: 31412032
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia
Study: 26509769
Drug: Carbomer-based lipid-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer-based lipid-containing artificial tear formulations (CBLAT) in the switching group
Study: 26509769
Drug: Carbomer-based lipid-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer-based lipid-containing artificial tear formulations (CBLAT) in the add-on group
Study: 15310534
Drug: Combination hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination hormone therapy (conjugated equine estrogen, 0.625 mg, and medroxyprogesterone, 2.5 mg)
Study: 1864667
Drug: K-strophanthidin (0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-strophanthidin (0.008 mg/kg for 5-10 min)
Study: 31833801
Drug: Originator insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator insulin aspart (NN-Asp)
Study: 27684440
Drug: ADT +
Normalized name: Antidepressant+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT + metformin
Study: 18761778
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (2.2 g total fatty acids/d)
Study: 18761778
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil (2.2 g total fatty acids/d)
Study: 31465585
Drug: Dimethylfumarate (DMF)
Normalized name: dimethylcarbate
DrugBank: Dimethyl carbate (DB13204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylfumarate (DMF) 720 mg daily
Study: 26334856
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of methylprednisolone intravenously before CPB
Study: 26334856
Drug: Standard CABG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CABG surgery without any additional medication (Control)
Study: 19225268
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg/day) for 2 months
Study: 17414740
Drug: Amisulpride (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200-800 mg/day)
Study: 11232746
Drug: Haloperidol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-20 mg/day)
Study: 8409060
Drug: Albunex 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex 0.08 ml/kg
Study: 8409060
Drug: Albunex 0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex 0.22 ml/kg
Study: 26522081
Drug: High-Ca group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Ca group (same milk powder additionally fortified with 600 mg of Ca)
Study: 20159379
Drug: Ultrarapid IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrarapid IV hydration (50 mL/kg normal saline for 1 hour)
Study: 20159379
Drug: Standard IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IV hydration (50 mL/kg normal saline for 3 hours)
Study: 17654232
Drug: Antioxidant-supplemented group
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-supplemented group (500 mg/day of vitamin E, 30 mg/day of beta-carotene, and for the last 15 days, 1 g/day of vitamin C)
Study: 10412891
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg E2 plus 0.15 mg DSG tablets
Study: 7751882
Drug: Eight-drugs-in-1-day chemotherapy
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight-drugs-in-1-day chemotherapy without RT
Study: 7751882
Drug: Craniospinal RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniospinal RT and chemotherapy (vincristine, lomustine (CCNU), and prednisone)
Study: 85937
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid 250 mg/day
Study: 388396
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg b.d.
Study: 388396
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tienilic acid 250 mg/day and propranolol 80 mg b.d.
Study: 30635070
Drug: Historic control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historic control group (postoperative adjuvant chemotherapy)
Study: 17389757
Drug: Peptide inhalation
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide inhalation
Study: 11487742
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (345 mg/d)
Study: 9726699
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 5 days
Study: 30260776
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of sequential therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid for 5 d, followed by pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for additional 5 d)
Study: 30260776
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of triple therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid)
Study: 15721471
Drug: Head cooling
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head cooling for 72 h, within 6 h of birth, with rectal temperature maintained at 34‐35 degrees C (n=116)
Study: 12869909
Drug: Clindamycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (10 days therapy)
Study: 2050231
Drug: Topical 13‐cis‐retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 13‐cis‐retinoic acid
Study: 28544581
Drug: Reference medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference medication (60 mg)
Study: 28544581
Drug: MPH XR‐ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH XR‐ODT and Reference medication
Study: 7992348
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole
Study: 7992348
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mebendazole
Study: 11145488
Drug: Rivastigmine (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (6-12 mg daily)
Study: 31594738
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention to promote CC screening
Study: 26588006
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication dispenser (EMD) used for 1 year
Study: 26588006
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication dispenser (EMD)
Study: 19690954
Drug: H ‐‐>
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H ‐‐> H + D (trastuzumab monotherapy followed by trastuzumab plus docetaxel)
Study: 18555937
Drug: G-ER BID
Normalized name: quinidine gluconate Extended Release Oral Tablet [Quin-G]
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ER BID (600 mg at 8 am and 1200 mg at 8 pm)
Study: 18555937
Drug: G-IR TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-IR TID (600 mg at 8 am, 2 pm, and 8 pm)
Study: 11907659
Drug: Constant inflation
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant inflation flow (CF) at 0.40 l/s
Study: 11907659
Drug: Decelerating inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decelerating inflation flow (DF) at 0.70 l/s
Study: 11907659
Drug: Decelerating inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decelerating inflation flow (DF) at 1.10 l/s
Study: 6849209
Drug: Metronidazole +
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole + Gentamicin (M + G)
Study: 6849209
Drug: Clindamycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin + Gentamicin (C + G)
Study: 28161147
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg/0.05 ml)
Study: 27814737
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose monohydrate, daily for 3 months)
Study: 24443804
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (IA-HA) injection once a week for five weeks
Study: 24443804
Drug: Oral non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral non-steroidal anti-inflammatory drugs (NSAIDs) three times per day for five weeks
Study: 24443804
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (IA-HA) injection
Study: 795608
Drug: Three drug
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drug schemes including 1 tablet t.d.s. (three times daily)
Study: 21685187
Drug: Candidate SNPs
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate SNPs within cholinergic receptors, nicotinic, alpha 3/5 (CHRNA3/CHRNA5)
Study: 19297141
Drug: Prednisolone 40mg
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 40mg once daily for 2 weeks
Study: 10487800
Drug: Lovastatin (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (33 mg/day)
Study: 1691811
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by radiotherapy (arm A)
Study: 2451713
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy and radiotherapy (arm B)
Study: 25649967
Drug: Advice meeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice meeting Institute of Medicine recommendations
Study: 21922138
Drug: 520 mg
Normalized name: aspirin 520 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 520 mg of ferrous sulfate once a day
Study: 17591659
Drug: Ketamine 0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.27 mg/kg
Study: 17591659
Drug: Ketamine 0.081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.081 mg/kg
Study: 16671337
Drug: Benazepril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10-20 mg/day) or Imidapril (5-10 mg/day) for 6 weeks
Study: 12200950
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block with bupivacaine 0.5% hyperbaric solution 10 mg (n = 20)
Study: 7634515
Drug: Gentamicin 4
Normalized name: gentamicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4 mg/kg q24h iv
Study: 7634515
Drug: Netilmicin 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 5.5 mg/kg q24h iv
Study: 31100353
Drug: Primary IOL
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary IOL treatment in unilaterally affected eyes (pre-IATS)
Study: 31100353
Drug: Primary IOL
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary IOL treatment in unilaterally affected eyes (post-IATS)
Study: 31100353
Drug: Primary IOL
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary IOL treatment in bilaterally affected eyes (pre-IATS)
Study: 31100353
Drug: Primary IOL
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary IOL treatment in bilaterally affected eyes (post-IATS)
Study: 31100353
Drug: Year-wise calculation
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Year-wise calculation of primary IOL treatment
Study: 25638526
Drug: Mean doses
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean doses to BOT, OC, and VP
Study: 22348833
Drug: 3-day omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day omeprazole administration
Study: 22348833
Drug: 3-day famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day famotidine administration
Study: 29774169
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily
Study: 19687332
Drug: Everolimus 70
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 70 mg weekly
Study: 17606174
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine trials
Study: 17606174
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine trials
Study: 12779186
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy plus education
Study: 28239984
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR‐NTX) for 78 weeks
Study: 26521574
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation training and medication (Control group).
Study: 9934936
Drug: Half-cycle sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-cycle sertraline dosing
Study: 9934936
Drug: Full-cycle sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-cycle sertraline dosing
Study: 7776527
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1.5 mg.kg‐1 2 minutes before laryngoscopy
Study: 7776527
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 4 micrograms.kg‐1
Study: 2157364
Drug: Cisplatin, vindesine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, vindesine and mitomycin combination regimen
Study: 74352
Drug: (+)-cyanidanol-3 (1.5g
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-cyanidanol-3 (1.5g daily)
Study: 26120075
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 g daily for 5 days)
Study: 23890767
Drug: Viscum album
Normalized name: Viscum album
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscum album [L.] extract (VaL) therapy
Study: 23890767
Drug: Viscum album
Normalized name: Viscum album
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscum album [L.] extract (VaL) therapy in 'good' prognosis subgroup
Study: 23890767
Drug: No antineoplastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antineoplastic therapy (control) in 'poor' prognosis subgroup
Study: 12407061
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (group 3)
Study: 3816876
Drug: Once-a-day dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day dosing (15 mg metaclazepam in the evening)
Study: 3816876
Drug: Twice-a-day dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day dosing (5 mg in the morning plus 10 mg in the evening)
Study: 26691837
Drug: Trastuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (6 mg/kg, single intravenous infusion over 90 min)
Study: 21813569
Drug: Transfer into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transfer into an open cot at 1600 g
Study: 6323087
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg intravenous injection)
Study: 6323087
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg oral dosing)
Study: 6323087
Drug: Ranitidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (0.5 microgram/ml serum concentration)
Study: 30604091
Drug: Lilly insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lilly insulin glargine (LY IGlar)
Study: 21490024
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (OOXY)
Study: 16766975
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (VAC) for hematomas
Study: 11134474
Drug: Adderall (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall (0.15 mg/kg/dose and 0.3 mg/kg/dose)
Study: 31640452
Drug: Office-based placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based placebo therapy (OBPT)
Study: 26602318
Drug: Blueberry treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry treatment (300g of blueberries) + smoking (one cigarette)
Study: 25263326
Drug: Smoking treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking treatment (one cigarette)
Study: 20542854
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of outcome measures
Study: 18447217
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Yueyueshu Decoction
Study: 15805349
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at 67 microg/kg per day
Study: 15805349
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at 33 microg/kg per day
Study: 12412977
Drug: BDP-HFA (beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP-HFA (beclomethasone dipropionate aerosol spray 500 microg b.i.d. via Jet spacer)
Study: 3378514
Drug: Atenolol 50mg
Normalized name: ATENOLOL 50MG TAB
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 50mg twice daily
Study: 26501499
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (N = 33)
Study: 19716278
Drug: LABA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA treatment
Study: 7669477
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine 3.5 ml
Study: 2257867
Drug: SCR 4
Normalized name: Sildenafil citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCR 4 mg
Study: 2257867
Drug: SCR 8
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCR 8 mg
Study: 2257867
Drug: SCR 4
Normalized name: Sildenafil citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCR 4 mg and SCR 8 mg
Study: 36117
Drug: Lorazepam 2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2-2.5 mg
Study: 3287911
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg once daily for two days, then 20 mg daily for five days
Study: 3287911
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for five days
Study: 17002709
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (200 mcg once daily for 4 weeks)
Study: 15284344
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 ml saline)
Study: 9113184
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 1.25 micrograms/kg
Study: 2868812
Drug: Intracoronary propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary propranolol (1.1 +/- 0.2 mg)
Study: 2868812
Drug: Intracoronary placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary placebo (saline, 2 ml)
Study: 8602564
Drug: Verapamil retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil retard 360 mg/day
Study: 1707230
Drug: Low-dose Adriamycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Adriamycin (doxorubicin, 20 mg/m2) alone
Study: 1707230
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with bleomycin and vincristine (ABV)
Study: 18408049
Drug: Nebulised furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised furosemide 40 mg
Study: 8000815
Drug: 15% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% glucose solution (1 g kg‐1 body mass)
Study: 3291901
Drug: Continuous-course treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-course treatment (212 patients)
Study: 20961748
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound therapy
Study: 27027660
Drug: Single-session psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session psychoeducation treatment
Study: 21939626
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion (HHS) 2 ml/kg (7.2% NaCl with 6% hydroxyethyl starch) over 10 min
Study: 21939626
Drug: HES infusion
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES infusion over 10 min